Catalyst Pharmaceuticals (NASDAQ:CPRX) Receives Overweight Rating from Stephens

Stephens reissued their overweight rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Thursday morning,Benzinga reports. They currently have a $33.00 target price on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Bank of America reaffirmed a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. HC Wainwright boosted their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Truist Financial upped their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $21.66 on Thursday. The stock has a fifty day moving average of $22.21 and a 200-day moving average of $21.40. The stock has a market capitalization of $2.58 billion, a P/E ratio of 18.36, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals has a 52 week low of $14.16 and a 52 week high of $24.64.

Insider Buying and Selling

In other news, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CPRX. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $27,000. Farther Finance Advisors LLC boosted its holdings in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $65,000. Finally, KBC Group NV lifted its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.